Compounds > 3-(15-hydroxypentadecyl)-2-4-4-trimethyl-2-cyclohexen-1-one

3-(15-hydroxypentadecyl)-2-4-4-trimethyl-2-cyclohexen-1-one and Diabetic-Neuropathies

3-(15-hydroxypentadecyl)-2-4-4-trimethyl-2-cyclohexen-1-one has been researched along with Diabetic-Neuropathies* in 1 studies

Other Studies

1 other study(ies) available for 3-(15-hydroxypentadecyl)-2-4-4-trimethyl-2-cyclohexen-1-one and Diabetic-Neuropathies

Article	Year
Beneficial action of 2,4,4-trimethyl-3-(15-hydroxypentadecyl)-2-cyclohexen-1-one, a novel long-chain fatty alcohol, on diabetic hypoalgesia and neuropathic hyperalgesia. Journal of pharmacological sciences, 2006, Volume: 102, Issue:2 The effects of 2,4,4-trimethyl-3-(15-hydroxypentadecyl)-2-cyclohexen-1-one (tCFA15) on diabetic hypoalgesia and neuropathic hyperalgesia were examined. Treatments of streptozotocin (STZ)-pretreated mice with tCFA15 (8 - 40 mg/kg, i.p.) for 7 days significantly reversed the depressed inflammatory nociceptive licking response in the formalin test. In addition, similar drug treatments and dosing in 7-day postoperative neuropathic pain model rats (prepared by the method of Bennett and Xie) yielded a similarly favorable outcome by significantly reversing decreased nociceptive thresholds in the paw pressure test. These results suggest that tCFA15 may have the potential to normalize sensory nerve abnormalities induced in experimental diabetes and nerve injury. Topics: Analgesics; Animals; Cyclohexanones; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Fatty Alcohols; Hyperalgesia; Male; Mice; Mice, Inbred Strains; Pain Threshold	2006

Article

Year

Beneficial action of 2,4,4-trimethyl-3-(15-hydroxypentadecyl)-2-cyclohexen-1-one, a novel long-chain fatty alcohol, on diabetic hypoalgesia and neuropathic hyperalgesia.

Journal of pharmacological sciences, 2006, Volume: 102, Issue:2

The effects of 2,4,4-trimethyl-3-(15-hydroxypentadecyl)-2-cyclohexen-1-one (tCFA15) on diabetic hypoalgesia and neuropathic hyperalgesia were examined. Treatments of streptozotocin (STZ)-pretreated mice with tCFA15 (8 - 40 mg/kg, i.p.) for 7 days significantly reversed the depressed inflammatory nociceptive licking response in the formalin test. In addition, similar drug treatments and dosing in 7-day postoperative neuropathic pain model rats (prepared by the method of Bennett and Xie) yielded a similarly favorable outcome by significantly reversing decreased nociceptive thresholds in the paw pressure test. These results suggest that tCFA15 may have the potential to normalize sensory nerve abnormalities induced in experimental diabetes and nerve injury.

Topics: Analgesics; Animals; Cyclohexanones; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Fatty Alcohols; Hyperalgesia; Male; Mice; Mice, Inbred Strains; Pain Threshold

2006